Nonsteroidal anti-inflammatory drugs (NSAID) sparing effects of glucosamine hydrochloride through n-glycosylation inhibition; Strategy to rescue stomach from nsaid damage

Journal of Physiology and Pharmacology

Volumn 64, Issue 2, 2013, Pages

  Park, S H ^a   Hong, H ^a   Han, Y M ^a,b   Kangwan, N ^a,b   Kim, S J ^a   Kim, E H ^a,b   Hahm, K B ^a  

^a CHA University   (South Korea)

^b Cha University   (South Korea)

Author keywords

Arthritis; COX 2 N glycosylation; Gastric damages; Glucosamine; Indomethacin

Indexed keywords

COLLAGEN TYPE 2; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; GLUCOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; MATRILYSIN; MESSENGER RNA; PROSTAGLANDIN E2; STROMELYSIN 3; TUMOR NECROSIS FACTOR ALPHA; TUNICAMYCIN; VASCULAR CELL ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME GLYCOSYLATION; MALE; MEDIATOR; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ULCER; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; GENETICS; GLYCOSYLATION; INFLAMMATION; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYCLOOXYGENASE 2; GLUCOSAMINE; GLYCOSYLATION; INDOMETHACIN; INFLAMMATION; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; STOMACH ULCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891677158     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-182.
2. Halverson PB. Nonsteroidal antiinflammatory drugs: benefits, risks, and COX-2 selectivity. Orthop Nurs 1999; 18: 21-26; quiz 27-28.
3. Arroyo M, Lanas A. NSAIDs-induced gastrointestinal damage. Review. Minerva Gastroenterol Dietol 2006; 52: 249-259.
4. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010; 39: 433-464.
5. Baumgartner HK, Starodub OT, Joehl JS, et al. Cyclooxygenase 1 is required for pH control at the mouse gastric surface. Gut 2004; 53: 1751-1757.
6. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
7. Halter F, Tarnawski AS, Schmassmann A, et al. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49: 443-453.
8. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994; 55: 662-675.
9. Chen CY, Chen TM, Shyu AB. Interplay of two functionally and structurally distinct domains of the c-fos AU-rich element specifies its mRNA-destabilizing function. Mol Cell Biol 1994; 14: 416-426.
10. Chen CY, Shyu AB. Selective degradation of early-response-gene mRNAs: functional analyses of sequence features of the AU-rich elements. Mol Cell Biol 1994; 14: 8471-8482.
11. Kang YJ, Mbonye UR, DeLong CJ, et al. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007; 46: 108-125.
12. Mbonye UR, Wada M, Rieke CJ, et al. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 2006; 281: 35770-35778.
13. Mbonye UR, Yuan C, Harris CE, et al. Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 2008; 283: 8611-8623.
14. de los Reyes GC, Koda RT, Lien EJ. Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: a survey. Prog Drug Res 2000; 55: 81-103.
15. Jang BC, Sung SH, Park JG, et al. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem 2007; 282: 27622-27632.
16. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-9788.
17. Itoh T, Matsuda H, Tanioka M, et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002; 169: 2643-2647.
18. Slomiany BL, Piotrowski J, Slomiany A. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Scand J Gastroenterol 1997; 32: 638-642.
19. Santhosh S, Anandan R, Sini TK, et al. Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats. J Gastroenterol Hepatol 2007; 22: 949-953.
20. Selvan T, Rajiah K, Nainar MS, et al. A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis. ScientificWorldJournal 2012; 2012: 902676.
21. Kwiecien S, Konturek PC, Sliwowski Z, et al. Interaction between selective cyclooxygenase inhibitors and capsaicin-sensitive afferent sensory nerves in pathogenesis of stress-induced gastric lesions. Role of oxidative stress. J Physiol Pharmacol 2012; 63: 143-151.
22. Takayama S, Izuhara C, Yamada N, et al. A new model of gastric bleeding induced in rats by aspirin plus clopidogrel under stimulation of acid secretion. Prophylactic effects of antiulcer drugs. J Physiol Pharmacol 2012; 63: 41-52.
23. Yu Y, Ricciotti E, Scalia R, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 2012; 4: 132ra154.
24. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322, 1322 e1311-1315.
25. Filaretova LP, Bagaeva TR, Morozova OY, et al. The healing of NSAID-induced gastric lesion may be followed by small intestinal and cardiovascular side effects. J Physiol Pharmacol 2011; 62: 619-625.
26. Spencer AG, Thuresson E, Otto JC, et al. The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis. J Biol Chem 1999; 274: 32936-32942.
27. Yuan C, Rieke CJ, Rimon G, et al. Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci USA 2006; 103: 6142-6147.
28. Xiao G, Chen W, Kulmacz RJ. Comparison of structural stabilities of prostaglandin H synthase-1 and-2. J Biol Chem 1998; 273: 6801-6811.
29. Otto JC, DeWitt DL, Smith WL. N-glycosylation of prostaglandin endoperoxide synthases-1 and-2 and their orientations in the endoplasmic reticulum. J Biol Chem 1993; 268: 18234-18242.
30. Mbonye UR, Song I. Posttranscriptional and posttranslational determinants of cyclooxygenase expression. BMB Rep 2009; 42: 552-560.
31. Sevigny MB, Li CF, Alas M, et al. Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett 2006; 580: 6533-6536.
32. DeWitt DL, Meade EA. Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch Biochem Biophys 1993; 306: 94-102.
33. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002; 68-69: 95-114.
34. Dixon DA, Tolley ND, King PH, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001; 108: 1657-1665.
35. Chakrabarty A, Tranguch S, Daikoku T, et al. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc Natl Acad Sci USA 2007; 104: 15144-15149.
36. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808.